Table 1.

Selected FDA-Approved TA-Targeted mAbs for Human Cancers

mAb	Target	Isotype	FDA-Approved Diseases
Cetuximab	EGFR/HER1	Chimeric IgG1	EGFR-positive colon cancer, HNC
Panitumumab	EGFR/HER1	Fully human IgG2	EGFR-positive colon cancer, HNC
Rituximab	CD20	Chimeric IgG1	CD20+ low-grade lymphoma, diffuse large B-cell lymphoma, follicular lymphoma
Trastuzumab	HER2/neu	Humanized IgG1	HER2/neu-positive breast cancer

Abbreviations: FDA, US Food and Drug Administration; mAbs, monoclonal antibodies; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; Ig, immunoglobulin; HNC, head and neck cancer.